π΅οΈ Leonabio, Inc. ($LONA)
SEC insider & ownership activity, last 12 months Β· CIK 1620463 Β· every row links its SEC filing
Over the last 12 months insiders sold $99K with no open-market buying against it. Mark James Litton sold $45K in discretionary trades (JanβMar). No red-flag 8-Ks in the window.
Monthly net open-market insider flow, last 12 months (up = net buying)
Insider flow
0 buyers, $0 (0 lots) Β· 5 sellers, $99K (10 lots)
| Insider | Buys | Bought | Sells | Sold | Last |
|---|---|---|---|---|---|
| Mark James Litton | 0 | β | 2 | $45K | Mar 4, 2026 |
| San Martin Javier | 0 | β | 2 | $21K | Mar 4, 2026 |
| Church Kevin | 0 | β | 2 | $13K | Mar 4, 2026 |
| Worthington Mark | 0 | β | 2 | $13K | Mar 4, 2026 |
| Renninger Robert | 0 | β | 2 | $7K | Mar 4, 2026 |
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| Sermonix Pharmaceuticals, Inc. | 36.9% | 13D | Aug 24, 2026 | filing β | |
| David J. Portman | 36.9% | 13D | Aug 24, 2026 | filing β | |
| Joseph Edelman | 20.0% | 13D | Aug 22, 2026 | filing β | |
| Perceptive Advisors LLC | 20.0% | 13D | Aug 22, 2026 | filing β | |
| Perceptive Life Sciences Master Fund, Ltd. | 16.5% | 13D | Aug 22, 2026 | filing β | |
| Anders Hove | 12.1% | 13G | Aug 20, 2026 | filing β | |
| ADAR1 Capital Management, LLC | 7.7% | 13G | May 15, 2026 | filing β | |
| Daniel Schneeberger | 7.7% | 13G | May 15, 2026 | filing β | |
| Acorn Bioventures 2, L.P. | 7.0% | 13G | Aug 20, 2026 | filing β | |
| Acorn Capital Advisors GP 2, LLC | 7.0% | 13G | Aug 20, 2026 | filing β | |
| Steven Michael Oliveira | 5.1% | 13G | Apr 16, 2025 | filing β | |
| Acorn Bioventures, L.P. | 5.1% | 13G | Aug 20, 2026 | filing β | |
| Acorn Capital Advisors GP, LLC | 5.1% | 13G | Aug 20, 2026 | filing β | |
| Perceptive Xontogeny Venture Fund II, LP | exited | 13D | Aug 22, 2026 | filing β |
Planned insider sales (Form 144)
| Seller | Planned | Approx. sale date | |
|---|---|---|---|
| Mark James Litton | $28K | Mar 4, 2026 | filing β |
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Other events (8.01) | Aug 26, 2026 | filing β |
| Earnings (2.02) | Aug 14, 2026 | filing β |
| Reg FD disclosure (7.01) | Aug 14, 2026 | filing β |
| Financial Statements and Exhibits (9.01) | Aug 14, 2026 | filing β |
| Shareholder vote (5.07) | Jun 22, 2026 | filing β |
| Earnings (2.02) | May 7, 2026 | filing β |
| Reg FD disclosure (7.01) | May 7, 2026 | filing β |
| Financial Statements and Exhibits (9.01) | May 7, 2026 | filing β |
| Earnings (2.02) | Mar 26, 2026 | filing β |
| Reg FD disclosure (7.01) | Mar 26, 2026 | filing β |
| Financial Statements and Exhibits (9.01) | Mar 26, 2026 | filing β |
| Officer/director changes (5.02) | Mar 18, 2026 | filing β |
| Shareholder vote (5.07) | Mar 18, 2026 | filing β |
| Other events (8.01) | Mar 18, 2026 | filing β |
| Financial Statements and Exhibits (9.01) | Mar 18, 2026 | filing β |
| Officer/director changes (5.02) | Jan 7, 2026 | filing β |
| Charter/bylaw changes (5.03) | Jan 7, 2026 | filing β |
| Reg FD disclosure (7.01) | Jan 7, 2026 | filing β |
| Other events (8.01) | Jan 7, 2026 | filing β |
| Financial Statements and Exhibits (9.01) | Jan 7, 2026 | filing β |
| Acquisition or disposition (2.01) | Dec 18, 2025 | filing β |
| Financial Statements and Exhibits (9.01) | Dec 18, 2025 | filing β |
| Material agreement (1.01) | Dec 18, 2025 | filing β |
| Unregistered equity sale (3.02) | Dec 18, 2025 | filing β |
| Reg FD disclosure (7.01) | Dec 18, 2025 | filing β |
| Other events (8.01) | Dec 18, 2025 | filing β |
| Financial Statements and Exhibits (9.01) | Dec 18, 2025 | filing β |
| Material agreement (1.01) | Dec 18, 2025 | filing β |
| Unregistered equity sale (3.02) | Dec 18, 2025 | filing β |
| Reg FD disclosure (7.01) | Dec 18, 2025 | filing β |